August 2, 2015
Recommended Topic Related To:

VPRIV

"The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

Hereditary angioede"...

VPRIV




PATIENT INFORMATION

  • Advise patients that VPRIV is a treatment that is given intravenously every other week. The infusion typically takes up to 60 minutes.
  • Advise patients that VPRIV may cause hypersensitivity reactions [see WARNINGS AND PRECAUTIONS].

Last reviewed on RxList: 5/21/2015
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


From WebMD